SS Innovations International Inc (SSII) Investment Analysis:

1. Executive Summary

The global medical technology landscape stands at a critical juncture in late 2025, characterized by a persistent dichotomy: the rapid advancement of robotic surgical capabilities versus the stagnation of accessibility due to prohibitive costs. Within this macroscopic context, SS Innovations International Inc. (SSII) has emerged not merely as a participant but as a potentially disruptive force, challenging the quarter-century monopoly held by Intuitive Surgical in the soft-tissue robotics space. This report provides an exhaustive investment analysis of SSII, a commercial-stage surgical robotics company based in Fort Lauderdale, Florida, with substantial operational roots in India. As of December 10, 2025, the company trades on the NASDAQ Capital Market, presenting a complex investment profile defined by triple-digit revenue growth, a pivotal regulatory catalyst in the form of a United States Food and Drug Administration (FDA) 510(k) submission, and a precarious liquidity position that necessitates immediate capital management strategies.

At its core, the investment thesis for SS Innovations rests on the democratization of surgical robotics. The current market leader, the Da Vinci system, has achieved ubiquity in top-tier academic medical centers in the developed world, yet the vast majority of hospitals globally—and indeed many community hospitals within the United States—remain priced out of this ecosystem. SSII’s flagship product, the SSi Mantra, is engineered to dismantle these barriers through a cost structure estimated at one-third that of incumbent systems, without sacrificing clinical utility. The system's unique open-console architecture and proven efficacy in complex cardiac procedures—a domain largely largely unpenetrated by robotic competition—provide strategic differentiation beyond price.

The immediate short-term outlook is dominated by regulatory risk and opportunity. On December 5, 2025, the company submitted a 510(k) premarket notification to the FDA. This strategic choice, prioritizing the 510(k) pathway over the lengthier De Novo classification, signals management's confidence that the SSi Mantra is substantially equivalent to existing predicate devices. This submission covers a broad spectrum of indications including general, urological, colorectal, gynecological, and, crucially, cardiac surgery. The successful clearance of this application would serve as a transformative valuation event, unlocking the world’s largest medical device market. Simultaneously, the company is pursuing CE Mark certification for the European Union, anticipated in the first half of 2026.

Financially, SSII is a study in hyper-growth constrained by capital resources. The company reported a staggering 192.5% year-over-year revenue increase in the third quarter of 2025, reaching $12.8 million, driven by the accelerating adoption of the SSi Mantra 3 system. Year-to-date revenue for the first nine months of 2025 stands at $28.0 million, a 123% increase over the prior period. However, this growth has come at the cost of continued operating losses, with a reported net loss of $9.7 million for the nine-month period. Most concerning is the balance sheet, which shows cash and cash equivalents dwindling to $5.7 million as of September 30, 2025, down from $11.4 million just one quarter prior. This burn rate implies a critical need for financing in the very near term, introducing significant dilution risk for current shareholders.

The market has reacted to this mix of high potential and high risk with extreme volatility. The stock has traded in a wide range of $3.02 to $22.42 over the past 52 weeks, settling near the $6.00 level in early December 2025. With a market capitalization fluctuating around $1.16 billion, the market is pricing in significant future success while heavily discounting for execution risk. The ownership structure provides a unique layer of validation; the company is majority-owned (approximately 58%) by its founder and CEO, Dr. Sudhir Srivastava, a renowned robotic cardiac surgeon. Furthermore, the presence of Dr. Frederic Moll, the founder of Intuitive Surgical, as a significant shareholder (approx. 11%) serves as a tacit industry endorsement of the technology's viability.

This report dissects these elements in granular detail, moving beyond surface-level metrics to analyze the underlying engineering, clinical, and economic drivers of the business. It evaluates the SSi Mantra's technical architecture against competitors, models the financial implications of various regulatory outcomes, and stress-tests the company's liquidity runway. The analysis concludes that while SSII presents a high-risk profile suitable only for speculative capital, the potential for asymmetric returns—driven by the unlocking of the "Global South" market and the penetration of high-margin US cardiac surgery—is substantial.

2. Business Drivers & Strategic Overview

The strategic architecture of SS Innovations is built upon three pillars: technological differentiation through the SSi Mantra system, a "Reverse Innovation" market entry strategy focusing on India as a launchpad, and a relentless focus on cost-efficiency to expand the Total Addressable Market (TAM) for robotic surgery. Understanding these drivers requires a deep dive into the engineering specifications of the product and the health economics of the target markets.

2.1 The SSi Mantra Surgical Robotic System

The SSi Mantra is not a mere clone of existing systems; it represents an evolutionary divergence in surgical robotics design, informed heavily by Dr. Srivastava’s decades of experience performing over 1,400 robotic cardiac procedures. The system is a modular, multi-arm platform designed to address the ergonomic and economic limitations of the current standard of care.

2.1.1 Modular Architecture and Arm Configuration

Unlike the monolithic patient carts of early-generation robots, the SSi Mantra utilizes a modular cart system. The system supports 3 to 5 robotic arms, each mounted on its own independent, self-balancing cart. This modularity is a critical business driver for several reasons. First, it allows for flexibility in the operating room (OR). In varied hospital infrastructure environments—particularly in older hospitals in India and emerging markets where OR sizes vary—the ability to position arms independently is a logistical advantage. Second, it creates a flexible capital expenditure model. A hospital can purchase a 3-arm system for urological procedures and upgrade to a 5-arm configuration later for complex cardiac work, lowering the initial barrier to entry. This contrasts with the fixed-arm configurations of many competitor systems that require a maximal upfront investment.

2.1.2 The Open-Console Revolution

Perhaps the most distinct feature of the SSi Mantra is its "Surgeon Command Centre." The incumbent Da Vinci system utilizes an immersive, closed console where the surgeon buries their face in a binocular viewfinder, effectively isolating them from the rest of the surgical team. In contrast, the SSi Mantra employs an open-faced console design featuring a large 32-inch 3D 4K high-definition monitor.

This design choice drives business value through enhanced safety and training. The "heads-up" display allows the surgeon to maintain peripheral vision of the patient and the assisting staff, facilitating better communication—a critical factor in preventing errors during complex surgeries. Furthermore, the console includes a secondary 23-inch 2D touchscreen monitor that integrates patient data, such as holographic overlays of CT or MRI scans, directly into the surgeon's workflow. This integration of pre-operative imaging with intra-operative execution is a key selling point for surgeons handling complex anatomies, such as in cardiac revascularization.

2.1.3 Cardiac Surgery: The Unclaimed Frontier

While robotic surgery has become standard for prostatectomies and hysterectomies, its penetration in cardiac surgery remains remarkably low, estimated at less than 1% of eligible procedures globally. The primary hurdles have been the cost of existing systems and the technical difficulty of manipulating robotic arms inside the thoracic cavity without haptic feedback or specialized instrumentation.

SSII has positioned the SSi Mantra specifically to conquer this frontier. The system is the only one in its class currently performing Totally Endoscopic Coronary Artery Bypass (TECAB) procedures on a routine basis in its installed markets. As of November 2025, over 390 cardiac procedures have been performed using the Mantra system. The business implication here is profound: by unlocking the high-value cardiac surgery market, SSII gains access to a premium reimbursement tier and a prestige factor that "general surgery" robots lack. The company’s focus on this segment differentiates it from Medtronic’s Hugo or CMR’s Versius, which are primarily targeting the soft-tissue abdominal market.

2.1.4 Telesurgery Capabilities

The SSi Mantra has demonstrated robust telesurgery capabilities, a feature that SSII is aggressively commercializing. In 2025, the company successfully completed the world's first intercontinental robotic cardiac telesurgery and the first telesurgery for weight loss. This is enabled by the "SSi Mantra Tele Surgeon Console," a compact, portable version of the command center that can be deployed remotely.

The strategic driver here is the alleviation of the global surgeon shortage. By enabling a specialist in a metropolitan center of excellence (e.g., New Delhi or New York) to operate on a patient in a rural or underserved location, SSII creates a "Hub-and-Spoke" business model. This increases the utilization rate of the robotic systems installed in remote hospitals, which might otherwise sit idle due to a lack of local expertise. High system utilization drives high consumable sales, which is the lifeblood of the robotic surgery revenue model.

2.2 The "India First" Market Strategy

SSII’s decision to incubate and commercialize in India before entering the US is a classic example of "Reverse Innovation." This strategy turns the constraints of the Indian market—extreme price sensitivity and high patient volumes—into competitive advantages.

2.2.1 Clinical Validation at Scale

Regulatory bodies like the FDA require extensive clinical data to prove safety and efficacy. Collecting this data in the US is prohibitively expensive due to high trial costs. By commercializing in India first, SSII has accumulated data from over 7,300 procedures across 138 installed systems as of November 2025. This massive real-world evidence database covers over 100 different types of surgeries. This volume of data, generated at a fraction of the cost of US clinical trials, significantly de-risks the regulatory submissions in the US and Europe.

2.2.2 Cost Arbitrage and Manufacturing

The company manufactures its systems and "SSi Mudra" instruments in India, leveraging the country's cost-effective engineering talent and supply chain. This allows SSII to price the Mantra system at roughly 35-40% of the cost of a Da Vinci system (approx. $500k - $700k in India vs. $1.5M - $2.5M for competitors). More importantly, the recurring cost of consumables is significantly lower. In price-sensitive markets, the high cost of "per-procedure" instruments often limits robotic surgery to wealthy patients. By lowering this OpEx barrier, SSII expands the TAM to include middle-tier hospitals and public sector healthcare facilities.

2.3 Intellectual Property and Competitive Landscape

The surgical robotics IP landscape is a minefield, with Intuitive Surgical holding thousands of patents. SSII’s strategy to navigate this involves the development of proprietary "SSi Mudra" instruments and unique control algorithms. The "Mudra" line includes staplers, energy devices, and specialized cardiac instruments that are chip-enabled to track usage and life cycles.

2.3.1 Competitor Analysis

• Intuitive Surgical (ISRG): The incumbent. Strengths: massive installed base, deep surgeon training ecosystem. Weaknesses: High capital and operating costs, closed ecosystem. SSII competes by offering a "good enough" or superior (in cardiac/ergonomics) experience at a fraction of the price.

• Medtronic (Hugo): A major threat due to Medtronic's bundling power. However, Hugo has faced rollout delays and technical teething issues. SSII arguably has a lead in cardiac capabilities.

• CMR Surgical (Versius): Also a modular system, strong in Europe/India. SSII competes directly with Versius in India but differentiates through its open console and cardiac focus.

2.4 Strategic Partnerships and Key Personnel

The alignment of management with shareholders is absolute. Dr. Sudhir Srivastava owns approximately 58% of the company. His dual role as CEO and lead clinical innovator ensures that product development is driven by clinical reality, not just engineering theory. The backing of Dr. Frederic Moll (11% ownership) is arguably the strongest intangible asset the company possesses. Dr. Moll’s involvement suggests that he sees SSII not just as another competitor, but as the platform that corrects the limitations of the industry he created.

3. Financial Performance & Valuation (2024-2025)

The financial profile of SS Innovations is characteristic of a company in the aggressive scaling phase of its lifecycle: explosive top-line growth, improving but still negative margins, and a cash-burn dynamic that necessitates careful scrutiny.

3.1 Revenue Trajectory and Composition

The revenue growth witnessed in 2025 confirms that the company has moved beyond the "proof of concept" phase into commercial scaling.

• Fiscal Year 2024 Baseline: For the full year ended December 31, 2024, SSII reported total revenue of $20.65 million. This served as the foundational year where the installed base began to achieve critical mass.

• Q1 2025 Performance: The momentum began accelerating in the first quarter, with revenue reaching $5.1 million, a 40.8% increase over the $3.6 million recorded in Q1 2024.

• Q2 2025 Inflection: The second quarter marked a significant step-change. Revenue doubled to $10.0 million, representing a 121.8% year-over-year increase. This surge was driven by the launch and uptake of the SSi Mantra 3 system.

• Q3 2025 Acceleration: The most recent quarter ended September 30, 2025, saw revenue climb to $12.8 million, a massive 192.5% increase compared to the $4.4 million in Q3 2024.

• Year-to-Date (9M) 2025: Cumulative revenue for the first nine months of 2025 stands at $28.0 million, up 123.0% from $12.5 million in the prior year period.

Analysis of Revenue Streams (Q3 2025 Detail): The composition of revenue is vital for understanding the sustainability of the business model.

• System Sales: $11.7 million (91% of total), up 194.9% YoY. This indicates the primary driver is still the placement of new capital equipment.

• Instrument Sales: $0.85 million, up 153.1% YoY. While still a small portion of the total, the triple-digit growth confirms that utilization rates on installed systems are rising.

• Warranty/Service: $0.24 million, up 317.4% YoY. This is a high-margin recurring revenue stream that will grow linearly with the installed base.

3.2 Profitability and Margin Analysis

SSII is navigating the difficult transition from gross margin volatility to operating leverage.

• Gross Margin Dynamics:

  • Q2 2025: Gross margin expanded significantly to 59.1%, up from 31.9% in the prior year. This expansion was attributed to economies of scale in manufacturing and a favorable product mix.

  • Q3 2025: Margins compressed sequentially to 48.1% (compared to 52.8% in Q3 2024). This contraction likely reflects the costs associated with ramping up production for new territories and potential introductory pricing strategies to capture market share in competitive regions.

  • Strategic Implication: The long-term target for robotic surgery companies is typically 65-70%. SSII's current range of 48-59% is healthy for its stage but needs to stabilize upward as instrument revenue (which typically carries higher margins) becomes a larger part of the mix.

• Operating Expenses and Net Loss:

  • Q3 2025 Net Loss: The company reported a net loss of $3.7 million ($(0.02) per share), widening slightly from the $3.2 million loss in Q3 2024. Despite nearly tripling revenue, the loss expanded, indicating that Operating Expenses (R&D, Sales & Marketing, G&A) are scaling in lockstep with revenue. This is typical for a company funding a global launch and FDA regulatory process simultaneously.

  • 9M 2025 Net Loss: On a year-to-date basis, the picture improves. The net loss for the first nine months was $9.7 million, a significant reduction from the $17.2 million loss in the same period of 2024. This demonstrates that operating leverage is beginning to take hold—revenue is growing faster than expenses on an annual basis.

3.3 Liquidity and Capital Resources (The Critical Risk)

The balance sheet as of September 30, 2025, reveals a liquidity position that is the single greatest risk factor for investors.

• Cash Position: Cash and cash equivalents stood at $5.7 million.

  • Context: This is a sharp decline from the $11.4 million reported just one quarter earlier (June 30, 2025).

  • Burn Rate: The implied cash burn for Q3 was roughly $5.7 million.

  • Runway: At this burn rate, the company has approximately one quarter of cash remaining from the end of September. By the time of this report (December 2025), the company is likely in immediate need of capital or has already drawn on credit facilities/equity lines not yet reported.

• Working Capital Strain: Inventory surged to $20.0 million as of September 30, 2025, up from $10.2 million at the end of 2024. This doubling of inventory ties up $10 million in cash. While this inventory is necessary to fulfill the growing order book (27 systems installed in Q3), it represents a massive drag on liquidity.

• Debt Profile: The company reports $0 in long-term debt, which is a silver lining. It implies the company has an unlevered balance sheet that could support debt financing, preventing immediate massive equity dilution. However, short-term liabilities (bank overdrafts, accounts payable) remain a pressure point.

3.4 Valuation

Valuing SSII is an exercise in probability-weighting its future cash flows, as current earnings are negative.

• Market Capitalization: Approximately $1.16 billion at a share price of ~$6.00.

• Revenue Multiple (P/S):

  • Estimated FY 2025 Revenue: ~$40 - $45 million (assuming Q4 matches or exceeds Q3).

  • Forward P/S Ratio: ~26x - 29x.

  • Comparative: Intuitive Surgical (ISRG) typically trades at 15x - 20x forward sales.

• Analysis: SSII trades at a significant premium to the industry leader on a sales basis. This premium is the "growth tax"—investors are paying for the 100%+ growth rate compared to ISRG's ~15%. However, a 26x multiple leaves zero margin for error. Any stumble in revenue growth or regulatory delays could cause a swift re-rating to a 10x-15x multiple, implying a 50% downside in share price. Conversely, FDA approval could justify the premium by unlocking the US market, potentially driving the multiple higher or sustaining it on a much larger revenue base.

Table 3.1: Quarterly Financial Progression (2024-2025)

Source: Derived from SEC filings and press releases.

4. Risk Assessment & Macroeconomic Considerations

Investing in SSII carries a specialized risk profile that combines the binary regulatory outcomes of a biotech firm with the manufacturing and scaling challenges of an industrial hardware company.

4.1 Regulatory Risk: The 510(k) Pathway

The submission of the 510(k) notification in December 2025 is the company's defining moment.

• The Mechanism: The 510(k) pathway requires SSII to prove that the SSi Mantra is "substantially equivalent" to a legally marketed device (the predicate), almost certainly the Da Vinci system.

• The Risk: If the FDA determines that the technological differences (e.g., the open console, different arm architecture) raise new questions of safety or efficacy, they could reject the 510(k) and mandate a De Novo classification.

• Consequence: A shift to De Novo would likely require a new, prospective clinical trial in the US, costing tens of millions of dollars and delaying market entry by 18-24 months. This would be a catastrophic blow to the stock price given the current cash burn.

• Mitigation: The company has completed a human factors validation study at Johns Hopkins University, a top-tier US institution, to support its submission. The robust clinical data from India (7,300+ procedures) also strengthens the safety argument, although the FDA prioritizes US data.

4.2 Liquidity and Dilution Risk

As highlighted in the financial section, the company is running on fumes.

• Immediate Dilution: To survive 2026, SSII must raise capital. An equity raise at current levels (~$6.00/share) would be dilutive. If the stock price drops further before a raise, the dilution becomes punitive (a "death spiral").

• Warrants and Overhang: While specific warrant tables are not fully detailed in the snippets, the existence of previous financing rounds typically involves warrants. As the stock price recovers, these warrants may be exercised, creating a ceiling on the stock price as shares flood the market.

4.3 Manufacturing and Supply Chain Concentration

• Single-Source Dependency: The company has acknowledged dependence on limited suppliers for key components. Any disruption in the supply of high-precision motors, optical sensors, or chips could halt production.

• Scaling Pains: Ramping from manufacturing ~10 systems a quarter to ~30+ brings quality control risks. A single recall or safety alert in the early stages of commercialization could permanently damage the brand's reputation, especially as a new entrant trying to prove reliability against a 20-year incumbent.

4.4 Macroeconomic and Geopolitical Factors

• India-US Relations: SSII manufactures in India. Currently, US-India relations are strong, with the "Initiative on Critical and Emerging Technology" (iCET) fostering cooperation. However, any future trade barriers, tariffs on medical device imports, or sanctions could destroy the cost advantage SSII enjoys.

• Currency Fluctuations: The company incurs costs in Indian Rupees (INR) but aims to generate substantial revenue in USD and Euros. A strengthening Rupee would compress margins, while a weakening Rupee would optically reduce reported revenue when consolidated in USD.

• Healthcare Spending Constraints: The core customer base in emerging markets is price-sensitive. A global recession or tightening of healthcare budgets in India/Middle East could freeze capital equipment purchasing, stalling SSII's growth engine.

5. 5-Year Scenario Analysis

This analysis projects potential trajectories for SSII through 2030 based on regulatory outcomes and market execution.

5.1 Scenario Inputs & Assumptions

• Current Shares Outstanding: ~194 Million.

• Dilution Assumption: 15% annual increase in share count to fund operations (reaching ~390M shares by 2030).

• Market Growth: Global surgical robotics market grows at 15% CAGR.

5.2 Scenario Descriptions

Base Case: "The Value Alternative" (50% Probability)

• Narrative: The FDA requires additional data but clears the 510(k) by late 2026. SSII captures 5-10% of the Indian market and establishes a foothold in US Ambulatory Surgery Centers (ASCs) and rural hospitals. It becomes the "Android" to Intuitive's "iOS"—a widely used, cost-effective alternative.

• Financials (2030): Revenue hits $650 Million. Gross margins stabilize at 60%. The company achieves consistent profitability with a 15% net margin.

• Valuation: Trades at roughly 6x Sales (discount to peers due to lower margins/market position).

High Case: "The Global Disruptor" (20% Probability)

• Narrative: FDA clearance is granted in Q1/Q2 2026 without major hurdles. The cardiac capabilities drive rapid adoption in Tier-1 US hospitals for bypass surgeries. Telesurgery becomes a reimbursed standard of care, and SSII dominates this niche. An acquisition by a major MedTech player (e.g., Stryker, J&J) becomes likely.

• Financials (2030): Revenue reaches $1.8 Billion. Margins expand to 70% (software/service mix). Net margin hits 25%.

• Valuation: Trades at a premium 30x P/E or 8x Sales, reflecting market leadership in cardiac robotics.

Low Case: "The Regional Player" (30% Probability)

• Narrative: FDA rejects the 510(k), forcing a multi-year De Novo trial the company cannot afford. SSII retreats to focus solely on India and unregulated markets. Cash crunch leads to toxic financing, wiping out early equity holders. Technology becomes commoditized by cheaper Chinese competitors.

• Financials (2030): Revenue stagnates at $150 Million. The company remains barely profitable or loss-making.

• Valuation: Trades at 2x Sales, reflecting lack of growth and liquidity risk.

Table 5.1: 5-Year Financial & Valuation Projections (2030)

Note: The Base Case suggests the stock is currently fairly valued or slightly ahead of itself given the execution risks, while the High Case offers multibagger potential.

6. Qualitative Scorecard

This scorecard rates SSII on critical intangible factors (Scale 1-10).

7. Conclusion & Investment Thesis

SS Innovations International Inc. presents one of the most compelling, yet perilous, risk/reward profiles in the medical device sector for 2025/2026.

The Bull Thesis: Investors are buying into the only credible, cost-effective alternative to Intuitive Surgical that has demonstrated the capability to perform high-complexity cardiac work. The validation from Dr. Frederic Moll cannot be overstated; his involvement signals that the SSi Mantra solves real clinical problems. If the FDA grants 510(k) clearance, the valuation ceiling lifts dramatically. The "India Strategy" provides a solid floor—even without the US, SSII can likely build a sustainable $100M+ revenue business in emerging markets, servicing the billions of people currently denied robotic surgery access.

The Bear Thesis: The company is effectively insolvent without immediate financing. The cash burn is high, and the reliance on a single regulatory submission is a classic failure point. If the FDA rejects the 510(k), the investment thesis for the US market collapses for at least two years, likely driving the stock into penny-stock territory.

Investment Verdict: SSII is rated as a Speculative Buy for sophisticated, risk-tolerant portfolios. It is not suitable for conservative capital. The current valuation (~$1.2B) prices in significant success, but implies a potential 5x-7x return in a "Blue Sky" scenario where it disrupts the US market. The recommended strategy is to monitor the liquidity situation closely; a successful capital raise that removes the near-term bankruptcy risk would be a significant buy signal, even if it comes at the cost of some dilution.

8. Technical Analysis, Price Action & Short-Term Outlook

Status (Dec 10, 2025): Bearish Consolidation with Potential for Reversal.

8.1 Price Action Context

The stock has corrected roughly 70% from its 52-week high of $22.42, a "valuation reset" common in high-growth small caps. The recent trading range of $5.90 - $6.50 represents a battleground between long-term believers and short-term liquidity fears.

8.2 Moving Averages

• 200-Day Moving Average (DMA): The stock is trading significantly below its 200 DMA (approx. $7.70 - $7.80). This confirms that the long-term trend remains bearish. The 200 DMA will act as formidable overhead resistance in any rally.

• 50-Day Moving Average: The price is hovering around the 50 DMA (~$6.20 - $7.16). A decisive close above the 50 DMA on high volume would act as the first technical signal that the downtrend has arrested.

8.3 Momentum Indicators

• RSI (Relative Strength Index): The RSI is currently neutral (approx. 43-51). This indicates a lack of immediate directional momentum—buyers are hesitant, but sellers are exhausted.

• MACD: The MACD is showing signs of a bullish convergence, potentially signaling a momentum shift if buying volume enters the market.

8.4 Support & Resistance Levels

• Resistance 1: $6.50 (Recent swing high). Breaking this level opens the path to $7.80.

• Resistance 2: $7.80 (200 DMA). This is the critical "breakout" level.

• Support 1: $5.90 (Recent consolidation floor). Holding this level is vital for the bullish case.

• Support 2: $3.02 (52-week low). A breach of $5.90 brings this catastrophic level into play.

8.5 Short-Term Outlook

Neutral to Slightly Bullish. The submission of the FDA 510(k) removes a major uncertainty overhang, potentially creating a "sell the rumor, buy the news" reversal or a stabilization floor. However, the technicals will remain constrained by the liquidity overhang. Traders should watch for a high-volume break above $6.50 as an entry trigger, with a strict stop-loss below $5.80. Long-term investors should view the current consolidation as an accumulation zone, provided they are comfortable with the dilution risk.

Disclaimer: This report is for informational purposes only and does not constitute financial advice. All investments involve risk, including the loss of principal.